Optimized Treatment Strategy for Depressive Disorder-Reference-Cited by-同舟云学术

Optimized Treatment Strategy for Depressive Disorder

Published:2019 Issue: Volume: Page:201-217
ISSN:0065-2598
Container-title:Advances in Experimental Medicine and Biology
language:
Short-container-title:

Author:

Chen Peijun

Publisher

Springer Singapore

Link

http://link.springer.com/content/pdf/10.1007/978-981-32-9271-0_11

Reference63 articles.

1. Aronson R, Offman HJ, Joffe RT, Naylor CD (1996) Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis. Arch Gen Psychiatry 53:842–848

2. Barbee JG, Jamhour NJ (2002) Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry 63:737–741

3. Bauer M, Dell’osso L, Kasper S, Pitchot W, Dencker Vansvik E, Köhler J, Jørgensen L, Montgomery SA (2013) J Affect Disord 151(1):209–219. Epub 27 Jun 2013

4. Bauer M, Adli M, Ricken R, Severus E, Pilhatsch M (2014) Role of lithium augmentation in the management of major depressive disorder. CNS Drugs 28(4):331–342, Apr 2014

5. Bedson E, Bell D, Carr D, Carter B, Hughes D, Jorgensen A, Lewis H, Lloyd K, McCaddon A, Moat S, Pink J (2014) Folate augmentation of Treatment–Evaluation for Depression (FolATED): randomised trial and economic evaluation. Health Technol Assess 18:1–159

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MALDI-TOF MS-based SNP assay used to determine the appropriate antidepression for Chinese patients;Journal of Pharmaceutical and Biomedical Analysis;2025-01

2. A Bibliometric and Visual Analysis of Single Nucleotide Polymorphism Studies in Depression;Current Neuropharmacology;2024-02

3. Salud mental de los estudiantes universitarios: episodio depresivo mayor;LATAM Revista Latinoamericana de Ciencias Sociales y Humanidades;2023-07-21

4. Decreased medial prefrontal cortex activity related to impaired novel object preference task performance following GALR2 and Y1R agonists intranasal infusion;Biomedicine & Pharmacotherapy;2023-05

5. The Endocannabinoid System as a Biomarker for Diagnostic and Therapeutic Applications in Depression and Anxiety;CNS & Neurological Disorders - Drug Targets;2023-03